Asthma Management Guidelines

Treatment Recommendations

The American Academy of Family Physicians recommends inhaled corticosteroids (ICS) as the preferred first-line controller medication for persistent asthma due to their superior effectiveness in improving asthma control compared to any other single long-term control medication 1
For intermittent asthma, the American Academy of Family Physicians suggests short-acting beta2-agonists (SABA) as needed for symptom relief, with no daily controller medication needed 1, 2
For mild persistent asthma, low-dose inhaled corticosteroids are the preferred treatment, according to the American Academy of Family Physicians 3, 1
For moderate persistent asthma, the American Academy of Family Physicians recommends low to medium-dose inhaled corticosteroids plus long-acting beta2-agonist (LABA) as the preferred option 2, 3
For severe persistent asthma, high-dose inhaled corticosteroids plus long-acting beta2-agonist are recommended by the American Academy of Family Physicians 2, 1

The American Academy of Family Physicians suggests that increasing use of SABA more than twice weekly or more than two nights monthly indicates inadequate control and the need to intensify anti-inflammatory therapy 3, 1
Assessing peak expiratory flow (PEF) is recommended by the Thorax journal to monitor treatment response 4
The Praxis Medical Insights guideline recommends scheduling follow-up visits to evaluate symptom control and adjust medications as needed 5

The American Academy of Family Physicians recommends oral systemic corticosteroids for moderate to severe exacerbations 3, 1
High-dose nebulized beta2-agonists are suggested by the Thorax journal for acute symptoms 4
The Thorax journal recommends considering adding nebulized ipratropium and intravenous aminophylline or salbutamol/terbutaline for life-threatening features 4

The Praxis Medical Insights guideline suggests that for patients with increased intraocular pressure who cannot use ICS, LTRAs are a viable non-steroid alternative 5
The Praxis Medical Insights guideline recommends considering subcutaneous immunotherapy as adjunctive treatment for patients with allergic asthma and controlled symptoms 1
The American Academy of Family Physicians suggests that for exercise-induced bronchoconstriction, long-term control of asthma is recommended, with specific medications prescribed if symptoms persist during exercise 2

The American Academy of Family Physicians recommends evaluating and treating comorbidities that can worsen asthma control, including allergic rhinitis, sinusitis, gastroesophageal reflux, and medication sensitivities 2
Annual influenza vaccinations are recommended by the American Academy of Family Physicians for patients with persistent asthma 2

An adult patient with intermittent asthma is identified when symptoms occur only with specific triggers (e.g., dust, perfume) and the physical examination is normal between episodes. 6

The National Asthma Education and Prevention Program (NAEPP) recommends that Step 1 (intermittent asthma) be treated with an as‑needed short‑acting beta‑agonist (SABA) only; no daily controller medication is required. 6
Inhaled salbutamol is the preferred SABA for intermittent asthma, providing rapid reversal of airflow obstruction and prompt symptom relief. [7][8]9
Salbutamol should be used only as needed, ideally ≤ 2 times per week (excluding prophylaxis before exercise). [7][8]
Salbutamol has an excellent safety profile supported by extensive clinical data. 10

Increase in SABA use to > 2 times per week (excluding exercise prophylaxis) signals inadequate control and warrants stepping up to low‑dose daily inhaled corticosteroid (Step 2). [7][8]9
Additional red‑flag criteria for stepping up include:
- Any limitation of daily activities. 6
- Need for oral corticosteroids. 6

Inhaled corticosteroids are reserved for Step 2 (mild persistent asthma) and higher steps; they are not indicated for intermittent disease. [6][10]
Leukotriene receptor antagonists (e.g., montelukast) are alternative options for mild persistent asthma (Step 2) but have no role in intermittent asthma. [6][7]9
Long‑acting anticholinergics (e.g., tiotropium) have no established role in Step 1 intermittent asthma and are used only as add‑on therapy in more severe, persistent asthma. 6
Long‑acting beta‑agonists (LABA) as monotherapy are never appropriate as first‑line treatment and increase mortality risk when used without concurrent inhaled corticosteroid. [7][8]

Teach proper inhaler technique to ensure effective drug delivery. 6
Advise avoidance of known environmental triggers (e.g., dust, perfume). [6][10]
Instruct patients to seek urgent care if severe symptoms do not respond to SABA. 6
Encourage self‑monitoring of SABA use and symptom patterns to detect early deterioration in asthma control. 6